Universal Biosensors and NDC Partner to Distribute Xprecia Prime in the USA
UBI (UBI) Share Update November 2024 Monday 18th
Universal Biosensors Partners with NDC for Xprecia Prime Distribution in USA
Universal Biosensors, Inc. (ASX: UBI) has taken a significant step in expanding its presence in the United States by partnering with National Distribution & Contracting, Inc. (NDC) to distribute its Xprecia Prime coagulation analyzer. This marks the first sale of Xprecia Prime in the USA, signaling a major milestone for the company.
Instant Summary:
- Universal Biosensors partners with NDC for Xprecia Prime distribution.
- First Xprecia Prime sales in the USA.
- NDC is a major healthcare supply chain solution in the USA.
- Two-year non-exclusive distribution deal with automatic extensions.
- Access to thousands of coagulation clinics and hospitals through NDC.
Partnership Details
Universal Biosensors, Inc. has announced a strategic partnership with National Distribution & Contracting, Inc. (NDC) to distribute the Xprecia Prime coagulation analyzer in the United States. This partnership is a significant development for Universal Biosensors as it marks the first sale of Xprecia Prime in the USA, a key market for the company.
NDC is one of the largest healthcare supply chain solutions in the United States, representing over 1,900 distribution partners. This partnership will provide Universal Biosensors with direct access to thousands of coagulation clinics and hospitals across the country, significantly expanding the reach of Xprecia Prime.
Deal Terms and Strategic Importance
The agreement with NDC is for a two-year non-exclusive term, with automatic one-year extensions unless terminated by either party. This flexible arrangement allows Universal Biosensors to continue exploring additional distribution opportunities while solidifying its foothold in the U.S. market.
John Sharman, CEO of Universal Biosensors, expressed confidence in the partnership, highlighting NDC's thorough product review process and the strategic importance of the U.S. market for Xprecia Prime. The company has also been actively recruiting key staff to build its U.S. Xprecia business, indicating a strong commitment to growth in this region.
About Xprecia Prime
The Xprecia Prime is a second-generation coagulation monitoring device designed for fast and reliable prothrombin time (PT) and International Normalised Ratio (INR) results. Its portability and ease of use make it an attractive option for healthcare providers. The device helps monitor the dosage of vitamin K antagonists in patients, ensuring safety and efficacy. With a global market of approximately 10 million warfarin users and over 300 million PT/INR tests conducted annually, Xprecia Prime represents a significant market opportunity.
The partnership with NDC is expected to have a positive impact on Universal Biosensors' stock, as it opens up significant market opportunities in the United States. The deal provides the company with a robust distribution network, potentially leading to increased sales and revenue. Investors may view this development as a strategic move that could enhance the company's market position and financial performance.
Investor Reaction:
Analysts are likely to react positively to the news, given the strategic importance of the U.S. market and the credibility of NDC as a distribution partner. The partnership is seen as a validation of Xprecia Prime's market potential, and investors may anticipate further growth opportunities as Universal Biosensors continues to expand its distribution network.
Conclusion:
Universal Biosensors' partnership with NDC marks a pivotal moment in the company's expansion strategy. Investors should keep an eye on the company's progress in the U.S. market and consider the potential long-term benefits of this strategic alliance. As Universal Biosensors continues to build its distribution network, the company is well-positioned to capitalize on the growing demand for coagulation monitoring devices.